Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: Population-based estimates for the year 2000 by period analysis

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 441-447

  Brenner, Hermann ^a   Arndt, Volker ^a  

^a GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; CANCER REGISTRY; EPIDEMIOLOGY; MASS SCREENING; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; STATISTICS; SURVIVAL; UNITED STATES;

AGED; EPIDEMIOLOGIC STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 14544297425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.148     Document Type: Article

References (32)

1. Swan J, Breen N, Coates RJ, et al: Progress in cancer screening practices in the United States. Results from the 2000 National Health Interview Survey. Cancer 97:1528-1540, 2003
2. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-2000), Bethesda, MD, National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, released April 2003
3. Brenner H, Gefeller O: An alternative approach to monitoring cancer patient survival. Cancer 78:2004-2010, 1996
4. Brenner H, Gefeller O, Hakulinen T: Period analysis for up-to-date cancer survival data: Theory, empirical evaluation, computational realization and applications. Eur J Cancer 40:326-335, 2004
5. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chronic Dis 8:699-712, 1958
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 58:457-481, 1958
7. Brenner H, Hakulinen T: Up-to-date longterm survival estimates of patients with cancer by period analysis. J Clin Oncol 20:826-832, 2002
8. Brenner H, Hakulinen T: Advanced detection of time trends in long-term cancer patient survival: Experience from 50 years of cancer registration in Finland. Am J Epidemiol 156:566-577, 2002
9. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 6:101-121, 1961
10. Henson DE, Ries LA: The relative survival rate. Cancer 76:1687-1688, 1995
11. Hakulinen T: Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38:933-942, 1982
12. Arias E: United States life tables, 2000. Natl Vital Stat Rep 51:1-38, 2002
13. Greenwood M: A report on the natural duration of cancer. London, Ministry of Health, His Majesty's Stationery Office, 1926
14. Brenner H, Hakulinen T, Gefeller O: Computational realization of period analysis for monitoring cancer patient survival Epidemiology 13: 611-612, 2002
15. Potosky AL, Feuer EJ, Levin DL: Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 23: 181-186, 2001
16. Brenner H: Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 360:1131-1135, 2002
17. Welch HG, Schwartz LM, Woloshin S: Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975-2978, 2000
18. Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878, 2003
19. Schröder FH, Bangma CH: The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 79:68-71, 1997 (suppl 1)
20. Gohagan JK, Prorok PC, Hayes RB, et al: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Control Clin Trials 21:251S-272S, 2000 (suppl 6)
21. de Koning HJ, Liem MK, Baan CA, et al: ERSPC: Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial, Int J Cancer 98:268-273, 2002
22. Hankey BF, Feuer EJ, Clegg LX, et al: Cancer surveillance series: Interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst 91:1017-1024, 1999
23. Etzioni R, Legler JM, Feuer EJ, et al: Cancer surveillance series: Interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91:1033-1039, 1999
24. Sarma AV, Schottenfeld D: Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol 20:3-9, 2002
25. Stephenson RA: Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 29:173-181, 2002
26. Chu KC, Tarone RE, Freeman HP: Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97:1507-1516, 2003
27. Harris R, Lohr KN: Screening for prostate cancer: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:917-929, 2002
28. Frankel S, Smith GD, Donovan J, et al: Screening for prostate cancer. Lancet 361:1122-1128, 2003
29. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
30. Roach M 3rd: Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur Urol 32:48-54, 1997 (suppl 3)
31. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
32. D'Amico AV, Moul J, Carroll PR, et al: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163-2172, 2003